Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis

Restorative Neurology and Neuroscience

Volumn 29, Issue 4, 2011, Pages 243-252

  Del Barco, Diana García ^a   Montero, Enrique ^b   Coro Antich, Rosa M ^c   Brown, Enma ^a   Suarez Alba, José ^a   Lopez, Laura ^d   Subirós, Nelvys ^a   Berlanga, Jorge ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c INSTITUTO DE NEUROLOGÍA Y NEUROCIRUGÍA   (Cuba)

^d Pathology Department of Institute of Nephrology   (Cuba)

Author keywords

EAE; EGF; GHRP 6; IGF 1; multiple sclerosis therapy

Indexed keywords

HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; MALONALDEHYDE; MOG PEPTIDE[35-55]; NEUROPEPTIDE; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; BRAIN; BRAIN TISSUE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; ENCEPHALITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS; FEMALE; FOLLOW UP; HOMOGENATE; IMMUNIZATION; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN LOCALIZATION; RAT; SCORING SYSTEM; SPINAL CORD; SURVIVAL RATE; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPIDERMAL GROWTH FACTOR; FEMALE; HORMONES; INSULIN-LIKE GROWTH FACTOR I; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; OLIGOPEPTIDES; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80051497474     PISSN: 09226028     EISSN: 18783627     Source Type: Journal    
DOI: 10.3233/RNN-2011-0595     Document Type: Article

References (76)

1. Allard, D., Figg, N., Bennett, M.R. & Littlewood, T.D. (2008). Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3 a and GSK3. J Biol Chem, 283(28), 19739-19747.
2. Alonso de Lecinana, M., Gutierrez, M., Roda, J.M., Carceller, F. & ez-Tejedor, E. (2006). Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci, 247(2), 121-129. (Pubitemid 44301259)
3. Berlanga, J., Cibrian, D., Guevara, L., Dominguez, H., Alba, J.S., Seralena, A., Guillen, G., Lopez-Mola, E., Lopez-Saura, P., Rodriguez, A., Perez, B., Garcia, D. & Vispo, N.S. (2007). Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond), 112(4), 241-250.
4. Berlanga, J., Lodos, J. & Lopez-Saura, P. (2002). Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents. Burns, 28(5), 435-442. (Pubitemid 34876873)
5. Berlanga, J., Prats, P., Remirez, D., Gonzalez, R., Lopez-Saura, P., Aguiar, J., Ojeda, M., Boyle, J.J., Fitzgerald, A.J. & Playford, R.J. (2002). Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage. Am J Pathol, 161(2), 373-379. (Pubitemid 36142145)
6. Bibollet-Bahena, O. & Almazan, G. (2009). IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3 K/mTOR/Akt and MEK/ERK pathways. J Neurochem, 109(5), 1440-1451.
7. Bizzozero, O.A., Reyes, S., Ziegler, J. & Smerjac, S. (2007). Lipid peroxidation scavengers prevent the carbonylation of cytoskeletal brain proteins induced by glutathione depletion. Neurochem Res, 32(12), 2114-2122. (Pubitemid 350059855)
8. Bjartmar, C., Wujek, J.R. & Trapp, B.D. (2003). Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci, 206(2), 165-171. (Pubitemid 36143722)
9. Bodart, V., Febbraio, M., Demers, A., McNicoll, N., Pohankova, P., Perreault, A., Sejlitz, T., Escher, E., Silverstein, R.L., Lamontagne, D. & Ong, H. (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res, 90(8), 844-849. (Pubitemid 34633875)
10. Bondy, C.A. & Cheng, C.M. (2004). Signaling by insulin-like growth factor 1 in brain. Eur. J. Pharmacol., 490(1-3), 25-31. (Pubitemid 38482159)
11. Braitch, M., Harikrishnan, S., Robins, R.A., Nichols, C., Fahey, A.J., Showe, L. & Constantinescu, C.S. (2009). Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand, 119(4), 239-245.
12. Bruck,W. & Stadelmann, C. (2005). The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol, 18(3), 221-224. (Pubitemid 40813746)
13. Caballero, M.E., Berlanga, J., Ramirez, D., Lopez-Saura, P., Gozalez, R., Floyd, D.N., Marchbank, T. & Playford, R.J. (2001). Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut, 48(1), 34-40. (Pubitemid 32042639)
14. Chitnis, T., Imitola, J. & Khoury, S.J. (2005). Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord, 5(1), 11-26. (Pubitemid 40403010)
15. Cibrian, D., Ajamieh, H., Berlanga, J., Leon, O.S., Alba, J.S., Kim, M.J., Marchbank, T., Boyle, J.J., Freyre, F., Garcia Del, B.D., Lopez-Saura, P., Guillen, G., Ghosh, S., Goodlad, R. A. & Playford, R.J. (2006). Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond), 110(5), 563-573. (Pubitemid 43736119)
16. Cohen, B.A. & Rivera, V.M. (2010). PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin, 26(4), 827-838.
17. Delarasse, C., Daubas, P., Mars, L.T., Vizler, C., Litzenburger, T., Iglesias, A., Bauer, J., Della, G.B., Schubart, A., Decker, L., Dimitri, D., Roussel, G., Dierich, A., Amor, S., Dautigny, A., Liblau, R. & Pham-Dinh, D. (2003). Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest, 112(4), 544-553. (Pubitemid 38056339)
18. Deleyrolle, L., Marchal-Victorion, S., Dromard, C., Fritz, V., Saunier, M., Sabourin, J. C., Tran Van, B.C., Privat, A. & Hugnot, J.P. (2006). Exogenous and fibroblast growth factor 2/epidermal growth factor-regulated endogenous cytokines regulate neural precursor cell growth and differentiation. Stem Cells, 24(3), 748-762. (Pubitemid 44464780)
19. Delgado-Rubin de Celix A., Chowen J.A., Argente J. & Frago, L.M. (2006). Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity. J Neurochem, 99(3), 839-849. (Pubitemid 44583443)
20. Delgado-Rubin, A., Chowen, J.A., Argente, J. & Frago, L.M. (2009). Growth hormone-releasing peptide 6 protection of hypothalamic neurons from glutamate excitotoxicity is caspase independent and not mediated by insulin-like growth factor I. Eur J Neurosci, 29(11), 2115-2124.
21. Esterbauer, H. & Cheeseman, K.H. (1990). Determination of aldehydic lipid peroxidation products: malonaldehyde and 4- hydroxynonenal. Methods Enzymol, 186, 407-421. (Pubitemid 20279982)
22. Frago, L.M. & Chowen, J.A. (2005). Basic physiology of the growth hormone/insulin-like growth factor axis. Adv Exp Med Biol, 567, 1-25.
23. Frago, L.M., Paneda, C., Dickson, S.L., Hewson, A.K., Argente, J.& Chowen, J.A. (2002). Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology, 143(10), 4113-4122. (Pubitemid 35244390)
24. Garcia Del, B.D., Perez-Saad, H., Rodriguez, V., Marin, J., Falcon, V., Martin, J., Cibrian, D. & Berlanga, J. (2010). Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model. Neurotox Res, Jan; 19(1), 195-209.
25. Giuliani, C., Saji, M., Bucci, I., Fiore, G., Liberatore, M., Singer, D.S., Monaco, F., Kohn, L.D. & Napolitano, G. (2006). Transcriptional regulation of major histocompatibility complex class I gene by insulin and IGF-I in FRTL-5 thyroid cells. J Endocrinol, 189(3), 605-615.
26. Guan, J. (2008). Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for ischemic brain injury. Recent Pat CNS Drug Discov, 3(2), 112-127.
27. Guan, J. (2010). Insulin-Like Growth Factor -1 (IGF-1) derived neuropeptides, a novel strategy for the development of phar maceuticals for managing ischemic brain injury. CNS Neurosci Ther. DOI: 10.1111/j.1755-5949. 2009.00128.x
28. Guan, J. & Gluckman, P.D. (2009). IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions. Br J Pharmacol, 157(6), 881-891.
29. Heck, S., Lezoualc'h, F., Engert, S. & Behl, C. (1999). Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem, 274(14), 9828-9835.
30. Hemmer, B. & Hartung, H.P. (2007). Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol, 62(4), 314-326. (Pubitemid 350105946)
31. Hoftberger, R., boul-Enein, F., Brueck, W., Lucchinetti, C., Rodriguez, M., Schmidbauer,M., Jellinger, K. & Lassmann, H. (2004). Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol, 14(1), 43-50. (Pubitemid 38200588)
32. Husemann, J., Loike, J.D., Anankov, R., Febbraio, M. & Silverstein, S.C. (2002). Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia, 40(2), 195-205. (Pubitemid 35337377)
33. Ito, T., Ito, N., Bettermann, A., Tokura, Y., Takigawa, M. & Paus, R. (2004). Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol, 164(2), 623-634. (Pubitemid 38364677)
34. Jonge de, N., Goumans, M.J., Lips, D., Hassink, R., Vlug, E.J., van der, M.R., Emmerson, C.D., Nijman, J., de, W.L. & Doevendans, P.A. (2006). Controlling cardiomyocyte survival. Novartis Found Symp, 274, 41-51.
35. Kenchappa, P., Yadav, A., Singh, G., Nandana, S. & Banerjee, K. (2004). Rescue of TNFalpha-inhibited neuronal cells by IGF- 1 involves Akt and c-Jun N-terminal kinases. J Neurosci Res, 76(4), 466-474. (Pubitemid 38584574)
36. Knapp, P.E. & Adams, M.H. (2004). Epidermal growth factor promotes oligodendrocyte process formation and regrowth after injury. Exp Cell Res, 296(2), 135-144. (Pubitemid 38624635)
37. Kooijman, R., Sarre, S., Michotte, Y. & de, K.J. (2009). Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke, 40(4), e83-e88.
38. Kurzawa, R., Glabowski, W., Baczkowski, T., Wiszniewska, B. & Marchlewicz, M. (2004). Growth factors protect in vitro cultured embryos from the consequences of oxidative stress. Zygote, 12(3), 231-240. (Pubitemid 39420852)
39. La, M.L., Munari, L.M. & Lovati, R. (2010). Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev, 5 CD004678.
40. Li, W., Quigley, L., Yao, D.L., Hudson, L.D., Brenner, M., Zhang, B.J., Brocke, S., McFarland, H.F. and Webster, H.D. (1998). Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects. J Neuropathol Exp Neurol, 57(5), 426-438. (Pubitemid 28237326)
41. Limesand, K.H., Barzen, K.A., Quissell, D.O. & Anderson, S.M. (2003). Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF. Cell Death Differ, 10(3), 345-355. (Pubitemid 36582372)
42. Marriott, J.J., Miyasaki, J.M., Gronseth, G. & O'Connor, P.W. (2010). Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 74(18), 1463-1470.
43. Mason, J.L., Ye, P., Suzuki, K., D'Ercole, A.J. & Matsushima, G.K. (2000). Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci, 20(15), 5703-5708. (Pubitemid 30636897)
44. Matsuzaki, H., Tamatani, M., Mitsuda, N., Namikawa, K., Kiyama, H., Miyake, S. & Tohyama, M. (1999). Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem, 73(5), 2037-2046. (Pubitemid 29491818)
45. Matthieu, J.M., Comte, V., Tosic, M. & Honegger, P. (1992). Myelin gene expression during demyelination and remyelination in aggregating brain cell cultures. J Neuroimmunol, 40(2, 3), 231-234.
46. Mehler, M.F. & Gokhan, S. (1999). Postnatal cerebral cortical multipotent progenitors: regulatory mechanisms and potential role in the development of novel neural regenerative strategies. Brain Pathol, 9(3), 515-526. (Pubitemid 29316291)
47. Mellergard, J., Edstrom, M., Vrethem, M., Ernerudh, J. & Dahle, C. (2010). Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler, 16(2), 208-217.
48. Morrow, S.A., Metz, L.M. & Kremenchutzky, M. (2009). High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci, 36(2), 213-215.
49. Niidome, T., Morimoto, N., Iijima, S., Akaike, A., Kihara, T. & Sugimoto, H. (2006). Mechanisms of cell death of neural progenitor cells caused by trophic support deprivation. Eur J Pharmacol, 548(1-3), 1-8.
50. Ninomiya, M., Yamashita, T., Araki, N., Okano, H. & Sawamoto, K. (2006). Enhanced neurogenesis in the ischemic striatum following EGF-induced expansion of transit-amplifying cells in the subventricular zone. Neurosci Lett, 403(1, 2), 63-67. (Pubitemid 43963254)
51. Pan, W. & Kastin, A.J. (1999). Entry of EGF into brain is rapid and saturable. Peptides, 20(9), 1091-1098. (Pubitemid 29424216)
52. Pang, Y., Zheng, B., Fan, L.W., Rhodes, P.G. & Cai, Z. (2007). IGF-1 protects oligodendrocyte progenitors against TNFalphainduced damage by activation of PI3 K/Akt and interruption of the mitochondrial apoptotic pathway. Glia, 55(11), 1099-1107. (Pubitemid 47204202)
53. Pedotti, R., DeVoss, J.J., Youssef, S., Mitchell, D., Wedemeyer, J., Madanat, R., Garren, H., Fontoura, P., Tsai, M., Galli, S.J., Sobel, R.A. & Steinman, L. (2003). Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci U S A, 100(4), 1867-1872. (Pubitemid 36254540)
54. Peng, H.,Wen, T.C., Tanaka, J., Maeda, N., Matsuda, S., Desaki, J., Sudo, S., Zhang, B. & Sakanaka, M. (1998). Epidermal growth factor protects neuronal cells in vivo and in vitro against transient forebrain ischemia- and free radical-induced injuries. J Cereb Blood Flow Metab, 18(4), 349-360. (Pubitemid 28166509)
55. Plata-Salaman, C.R. (1991). Epidermal growth factor and the nervous system. Peptides, 12(3), 653-663.
56. Platten, M., Ho, P.P.,Youssef, S., Fontoura, P., Garren, H., Hur, E.M., Gupta, R., Lee, L.Y., Kidd, B.A., Robinson,W.H., Sobel, R.A., Selley, M.L. & Steinman, L. (2005). Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science, 310(5749), 850-855. (Pubitemid 41567343)
57. Popovic, N., Schubart, A., Goetz, B.D., Zhang, S.C., Linington, C. & Duncan, I.D. (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol, 51(2), 215-223. (Pubitemid 34111444)
58. Prat, A. & Antel, J. (2005). Pathogenesis of multiple sclerosis. Curr Opin Neurol, 18(3), 225-230. (Pubitemid 40813747)
59. Raineteau, O., Rietschin, L., Gradwohl, G., Guillemot, F. & Gahwiler, B.H. (2004). Neurogenesis in hippocampal slice cultures. Mol Cell Neurosci, 26(2), 241-250. (Pubitemid 38781081)
60. Russo,V.C., Gluckman, P.D., Feldman, E.L. & Werther, G.A. (2005). The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev, 26(7), 916-943. (Pubitemid 41770158)
61. Scalabrino, G., Galimberti, D., Mutti, E., Scalabrini, D., Veber, D., De, R.M., Bamonti, F., Capello, E., Mancardi, G.L. & Scarpini, E. (2010). Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res, 1333, 64-71.
62. Smith, S., Francis, R., Guilbert, L. & Baker, P.N. (2002). Growth factor rescue of cytokine mediated trophoblast apoptosis. Placenta, 23(4), 322-330. (Pubitemid 41348525)
63. Sulkowski, G., browska-Bouta, B., Kwiatkowska-Patzer, B. & Struzynska, L. (2009). Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. Folia Neuropathol, 47(4), 329-337.
64. Takahashi, J.L., Giuliani, F., Power, C., Imai, Y. & Yong, V.W. (2003). Interleukin-1 beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol, 53(5), 588-595. (Pubitemid 36529432)
65. Teramoto, T., Qiu, J., Plumier, J.C. & Moskowitz, M.A. (2003). EGF amplifies the replacement of parvalbumin-expressing striatal interneurons after ischemia. J Clin Invest, 111(8), 1125-1132. (Pubitemid 36519930)
66. Tureyen, K., Vemuganti, R., Bowen, K.K., Sailor, K.A. & Dempsey, R.J. (2005). EGF and FGF-2 infusion increases post-ischemic neural progenitor cell proliferation in the adult rat brain. Neurosurgery, 57(6), 1254-1263.
67. van der,W.A., Butzkueven, H., Kolbe, S., Marriott, M., Alexandrou, E., Gresle, M., Egan, G. and Kilpatrick, T. (2010). Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther, 126(1), 82-93.
68. Vincent, A.M., Mobley, B.C., Hiller, A. & Feldman, E.L. (2004). IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis, 16(2), 407-416. (Pubitemid 38765100)
69. Wallberg, M., Bergquist, J., Achour, A., Breij, E. & Harris, R. A. (2007). Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol, 37(7), 1986-1995. (Pubitemid 47065134)
70. Wang, H., Marnett, L.J., Harris, T.M. and Rizzo, C.J. (2004). A novel synthesis of malondialdehyde adducts of deoxyguanosine, deoxyadenosine, and deoxycytidine. Chem Res Toxicol, 17(2), 144-149. (Pubitemid 38252493)
71. Wilczak, N., Ramsaransing, G.S., Mostert, J., Chesik, D. & de, K.J. (2005). Serum levels of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Mult Scler, 11(1), 13-15. (Pubitemid 40259969)
72. Wilson, H.C., Onischke, C. & Raine, C.S. (2003). Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. Glia, 44(2), 153-165. (Pubitemid 37345625)
73. Wong, R.W. & Guillaud, L. (2004). The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev, 15(2, 3), 147-156. (Pubitemid 38521250)
74. Zargari, M., Allameh, A., Sanati, M.H., Tiraihi, T., Lavasani, S. & Emadyan, O. (2007). Relationship between the clinical scoring and demyelination in central nervous system with total antioxidant capacity of plasma during experimental autoimmune encephalomyelitis development in mice. Neurosci Lett, 412(1), 24-28. (Pubitemid 46038548)
75. Zausinger, S.,Westermaier, T., Plesnila, N., Steiger, H.J. & Schmid- Elsaesser,R. (2003). Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen. Stroke, 34(6), 1526-1532. (Pubitemid 36693529)
76. Zheng, W.H., Kar, S., Dore, S. & Quirion, R. (2000). Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J Neural Transm Suppl, 60, 261-272. (Pubitemid 32037198)